Addressing IOP and QOL With LAL, iStent, and Dextenza

Show Description +

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Addressing IOP and QOL With LAL, iStent, and Dextenza

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Please log in to leave a comment.

More in Cataract

Decreasing the Medication Burden With iDose TR

John P. Berdahl, MD; Natalia Morales, MD; and Justin Schweitzer, OD, FAAO

Innovations in Drug Delivery: A Drug-Delivering IOL

I. Paul Singh, MD; and Douglas McGraw, DO

UNITYtime Podcast Episode 2: Exploring the UNITY® VCS|CS System

Lorraine M. Provencher, MD; and Arjan Hura, MD

Phacoemulsification With Real-Time Remote Collaboration

Ernesto Calvo, MD; Salomon Abouganem, MD; and Eric Rosenberg, DO